It was demonstrated to be an LXRα antagonist and displays efficacy in treating NAFLD as it significantly decreased TC accumulation and induced steatosis at 20 μM through modulation of LXRα, transcription factor SREBP-1c, and a battery of downstream target genes (Lin et al., 2018). This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.